[Novel HER2-Targeted Therapy Combined with Gold Nanoparticles]

Area of Science:

• Oncology
• Nanotechnology
• Immunotherapy

Background:

• Trastuzumab (Tmab) targets human epidermal growth factor receptor 2 (HER2)-positive cancers but is limited to HER2-high tumors and ineffective against resistant cases.
• Existing HER2-targeted therapies lack clinical efficacy in gastric cancer, highlighting an unmet need.
• Gold nanoparticles (AuNPs) offer stability and surface functionalization for medical applications, with known cytotoxic effects via autophagy and apoptosis.

Purpose of the Study:

• To develop and evaluate HER2-targeted gold nanoparticles (Tmab-AuNPs) as a novel therapeutic agent.
• To investigate the efficacy of Tmab-AuNPs against Trastuzumab-resistant and HER2-negative cancer cell lines.

Main Methods:

• Conjugation of Trastuzumab (Tmab) to gold nanoparticles (AuNPs) to create Tmab-AuNPs.
• Assessment of Tmab-AuNPs' antitumor effects on Trastuzumab-resistant gastric cancer cell lines.
• Evaluation of Tmab-AuNPs efficacy in HER2-negative gastric cancer cell lines with artificial HER2 overexpression.

Main Results:

• Tmab-AuNPs demonstrated significant antitumor activity against Trastuzumab-resistant cell lines.
• Tmab-AuNPs were effective in HER2-negative gastric cancer cells engineered to overexpress HER2.
• The study validates the potential of combining AuNPs with tumor-targeting antibodies.

Conclusions:

• Tmab-AuNPs exhibit potent therapeutic effects, potentially overcoming Trastuzumab resistance and expanding treatment to HER2-low/negative gastric cancers.
• This nanotechnology-based approach offers a promising strategy to address limitations in current HER2-targeted cancer therapy.
• Tmab-AuNPs represent a viable alternative for treating gastric cancers unresponsive to Trastuzumab.